Hennion & Walsh Asset Management Inc. Has $11.40 Million Stock Position in Indivior PLC $INDV

Hennion & Walsh Asset Management Inc. increased its stake in shares of Indivior PLC (NASDAQ:INDV) by 43.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 317,600 shares of the company’s stock after acquiring an additional 96,177 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Indivior were worth $11,395,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. CWM LLC bought a new stake in Indivior in the 3rd quarter valued at $25,000. Quarry LP acquired a new stake in Indivior in the 3rd quarter worth $26,000. Raymond James Financial Inc. bought a new position in shares of Indivior during the 2nd quarter worth about $26,000. GAMMA Investing LLC increased its holdings in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the period. Finally, Plato Investment Management Ltd acquired a new position in shares of Indivior during the third quarter valued at about $52,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Stock Performance

Shares of Indivior stock opened at $28.97 on Monday. The firm’s 50-day simple moving average is $32.80 and its 200-day simple moving average is $31.05. Indivior PLC has a twelve month low of $8.64 and a twelve month high of $38.00. The firm has a market cap of $3.62 billion, a P/E ratio of 17.66 and a beta of 0.83.

Indivior (NASDAQ:INDV) last posted its earnings results on Friday, February 27th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The business had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. On average, equities analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Insider Activity at Indivior

In related news, Director Mark Stejbach bought 775 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. This represents a 4.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David E. Wheadon bought 1,771 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were bought at an average price of $35.39 per share, with a total value of $62,675.69. Following the transaction, the director directly owned 14,395 shares in the company, valued at $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 5,842 shares of company stock valued at $203,342.

Wall Street Analyst Weigh In

Several research firms recently weighed in on INDV. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. Northland Securities set a $50.00 price target on Indivior in a report on Tuesday, January 20th. HC Wainwright raised their price objective on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley reissued an “overweight” rating and set a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Finally, Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.